Drug Eluting Balloons (DEB) Market Size, Share, Growth, And Industry Analysis, By Type (Peripheral DEBs & Coronary DEBs) By Application (Catheterization Laboratory, Hospital, Others) Regional Forecast From 2026 To 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

DRUG ELUTING BALLOONS (DEB) MARKET OVERVIEW

The global Drug Eluting Balloons (DEB) Market is anticipated to be worth USD 1.08 Billion in 2026. It is expected to grow steadily and reach USD 3.3 Billion by 2035. This growth represents a CAGR of 13.1% during the forecast period from 2026 to 2035.

The Drug Eluting Balloons (DEB) Market is experiencing steady growth as healthcare providers increasingly adopt minimally invasive vascular interventions for the treatment of coronary and peripheral artery diseases. Drug eluting balloons deliver antiproliferative medication directly to the vessel wall during angioplasty, helping reduce restenosis while avoiding the permanent implantation of metallic stents in selected clinical cases. Continuous innovation in balloon coating technologies, catheter design, and drug delivery efficiency has improved treatment outcomes and expanded clinical applications. Rising investments in interventional cardiology, increasing availability of specialized vascular treatment centers, and growing adoption of advanced endovascular procedures continue to strengthen demand for drug eluting balloons across developed and emerging healthcare markets.

The United States remains one of the most significant markets for drug eluting balloons due to its advanced healthcare infrastructure and high volume of cardiovascular interventions. More than 900,000 percutaneous coronary intervention procedures are performed annually across the country, creating sustained demand for innovative angioplasty devices. Cardiovascular disease affects over 130 million adults, making vascular intervention a critical component of healthcare delivery. Hospitals and catheterization laboratories continue investing in advanced imaging systems and minimally invasive treatment technologies to improve patient outcomes. Growing adoption of outpatient vascular procedures, expanding reimbursement support for selected interventions, and continuous product approvals contribute to the increasing utilization of drug eluting balloons throughout the United States.

KEY FINDINGS

LATEST TRENDS

Expanding Indications to Provide More Benefits to the Consumers of the Market

The Drug Eluting Balloons (DEB) Market is witnessing significant technological progress driven by advancements in drug coating formulations, balloon catheter engineering, and vascular intervention techniques. Manufacturers are focusing on improving drug transfer efficiency by developing advanced coating technologies that enable rapid and uniform delivery of therapeutic agents to diseased blood vessels during balloon inflation. This has enhanced procedural effectiveness while reducing residual drug loss during catheter navigation.

Paclitaxel-coated balloons continue to dominate commercial adoption due to their established clinical performance in preventing restenosis following angioplasty. At the same time, research into alternative therapeutic agents is expanding to improve long-term vessel healing and broaden treatment applications. Drug eluting balloons are increasingly used in treating in-stent restenosis, small vessel disease, peripheral artery disease, and complex vascular lesions where permanent stent implantation may not be the preferred treatment option.

Healthcare providers are increasingly favoring minimally invasive procedures because they reduce hospitalization time, accelerate patient recovery, and lower procedural complications. Hybrid operating rooms equipped with advanced imaging technologies have improved procedural precision during balloon angioplasty. Manufacturers are also introducing lower-profile balloon catheters that enhance navigation through complex vascular anatomy. Growing investment in clinical research, physician training programs, and next-generation catheter technologies continues to support innovation, making drug eluting balloons an increasingly important solution in modern interventional cardiology and vascular medicine.

• According to the World Health Organization (WHO, 2024), cardiovascular diseases account for approximately 17.9 million deaths annually, representing 32% of all global deaths. The rising disease burden is driving adoption of drug-eluting balloon (DEB) technologies to reduce restenosis rates by nearly 45% compared to traditional angioplasty, as noted by the European Society of Cardiology (ESC).

• As per the U.S. Food and Drug Administration (FDA, 2024), over 62% of coronary procedures performed in U.S. hospitals are now minimally invasive. This shift toward less invasive therapies has encouraged the adoption of DEBs, which reduce hospital stays by 30%, improving patient recovery time and procedural efficiency.

•   
•   
  

  Download Free Sample to learn more about this report

    

DRUG ELUTING BALLOONS (DEB) MARKET SEGMENTATION

The Drug Eluting Balloons (DEB) Market is segmented by type and application to evaluate product adoption across different vascular procedures and healthcare settings. By type, the market consists of Peripheral DEBs and Coronary DEBs, each designed to address specific vascular conditions and treatment requirements. Coronary products are primarily used during coronary angioplasty procedures, while peripheral products are developed for arteries outside the heart, including lower limb vessels. By application, the market includes Catheterization Laboratory, Hospital, and Others. Increasing demand for minimally invasive vascular procedures, advanced imaging technologies, and specialized cardiovascular treatment facilities continues to support growth across all market segments.

By Type

According to type, the market can be segmented into Peripheral DEBs & Coronary DEBs

• Peripheral DEBs: Peripheral DEBs hold a significant position in the Drug Eluting Balloons (DEB) Market as the number of patients diagnosed with peripheral artery disease continues to increase globally. These balloons are specifically designed for treating blocked or narrowed arteries in the legs and other peripheral blood vessels. Physicians increasingly prefer peripheral drug eluting balloons because they deliver therapeutic medication directly to the vessel wall while avoiding the placement of a permanent implant in selected clinical situations. The technology is widely used for femoropopliteal artery disease, below-the-knee interventions, and dialysis access maintenance procedures. Continuous improvements in balloon flexibility, catheter trackability, and drug coating stability have enhanced procedural performance. 

• Coronary DEBs: Coronary DEBs account for the leading share of the Drug Eluting Balloons (DEB) Market due to their extensive use in interventional cardiology. These devices are widely utilized during coronary angioplasty procedures for treating in-stent restenosis, small vessel disease, bifurcation lesions, and selected coronary artery conditions where permanent stent implantation may not be clinically appropriate. Growing prevalence of coronary artery disease, increasing patient preference for minimally invasive procedures, and continuous technological innovation have supported widespread clinical adoption. Modern coronary drug eluting balloons incorporate advanced coating technologies that enable rapid transfer of therapeutic agents during balloon inflation while maintaining consistent drug distribution. Healthcare providers continue adopting these products because they simplify treatment strategies in selected cases and support vessel healing without leaving additional metallic implants.

By Application

Based on application, the market can be divided into Catheterization Laboratory, Hospital, & Others.

• Catheterization Laboratory: Catheterization laboratories represent the dominant application segment in the Drug Eluting Balloons (DEB) Market because they perform a large volume of diagnostic and interventional cardiovascular procedures. These specialized facilities are equipped with advanced fluoroscopy systems, intravascular imaging technologies, and highly trained interventional cardiologists capable of performing complex angioplasty procedures. Drug eluting balloons are frequently used in catheterization laboratories for coronary interventions, peripheral vascular procedures, and treatment of restenosis. Continuous investment in digital imaging systems, robotic catheter navigation, and real-time procedural monitoring has further improved treatment precision.

• Hospital: Hospitals continue to hold a substantial share of the Drug Eluting Balloons (DEB) Market because they provide comprehensive cardiovascular care supported by multidisciplinary medical teams. Large hospitals perform emergency cardiac interventions, planned angioplasty procedures, peripheral vascular treatments, and postoperative patient monitoring under one integrated healthcare system. Drug eluting balloons are increasingly incorporated into hospital-based interventional cardiology departments due to growing demand for advanced vascular treatment options. Expansion of cardiovascular centers, modernization of operating rooms, and investment in hybrid procedure suites have strengthened adoption of these devices. Academic hospitals also play an important role in clinical research and physician training, encouraging wider utilization of innovative drug eluting balloon technologies.

• Others: The "Others" application segment includes ambulatory surgical centers, specialty cardiovascular clinics, vascular treatment centers, and research institutions. This segment continues to expand as healthcare systems increasingly promote outpatient treatment models for selected vascular procedures. Ambulatory facilities offer efficient scheduling, shorter patient stays, and streamlined procedural workflows, making them attractive for minimally invasive interventions. Specialty clinics equipped with advanced imaging systems are also increasing their use of drug eluting balloons for peripheral vascular treatments and follow-up procedures. Research organizations contribute by evaluating new balloon technologies, drug formulations, and catheter designs through clinical studies that support future product innovation. Continued investment in specialized outpatient cardiovascular services is expected to strengthen demand within this application segment.

MARKET DYNAMICS

Driving Factor

Rising prevalence of cardiovascular disease and increasing adoption of minimally invasive vascular procedures

The primary growth driver for the Drug Eluting Balloons (DEB) Market is the increasing global burden of cardiovascular disease, which continues to generate strong demand for advanced vascular intervention technologies. Heart disease remains one of the leading causes of hospitalization worldwide, resulting in millions of angioplasty procedures every year. Drug eluting balloons provide physicians with an effective treatment option for restoring blood flow while minimizing the need for permanent implants in selected patients.

Expanding healthcare investments have enabled hospitals and catheterization laboratories to acquire advanced interventional equipment and improve procedural capabilities. Aging populations, rising incidence of diabetes, hypertension, obesity, and chronic kidney disease continue to increase the number of patients requiring vascular treatment. Improvements in diagnostic imaging, earlier disease detection, and wider physician awareness regarding drug eluting balloon therapy further strengthen market growth across both coronary and peripheral vascular interventions.

• According to the European Medicines Agency (EMA, 2024), over 85 cardiovascular device approvals were granted in the European Union in 2023, a 28% increase from 2020. This regulatory encouragement promotes R&D in DEB technologies designed for safer, drug-based arterial interventions.

• The Centers for Disease Control and Prevention (CDC, 2024) reports that 6.5 million adults in the United States aged 40 years and older are living with PAD. The growing prevalence of PAD worldwide has led to an estimated 18% increase in DEB usage for peripheral interventions over the past five years, as cited by the American Heart Association (AHA).

Driver Impact Analysis

Rising Prevalence of Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD)

The increasing incidence of peripheral artery disease and coronary artery disease is one of the primary factors driving the Drug Eluting Balloons (DEB) market. An aging global population, sedentary lifestyles, diabetes, obesity, and hypertension are contributing to a growing number of patients requiring vascular interventions. Drug eluting balloons provide an effective treatment option by delivering antiproliferative drugs directly to diseased arteries without leaving a permanent implant. Healthcare providers are increasingly adopting these devices to reduce restenosis and improve long-term vessel patency. The expanding patient pool is encouraging manufacturers to increase production capacity and invest in advanced balloon technologies. Hospitals and catheterization laboratories are also broadening their interventional capabilities to meet rising procedural demand. Over the forecast period, the continued increase in cardiovascular disease prevalence is expected to sustain strong market growth worldwide.

Increasing Preference for Minimally Invasive Vascular Interventions

The healthcare industry is rapidly shifting toward minimally invasive procedures due to their ability to reduce surgical trauma, shorten hospital stays, and accelerate patient recovery. Drug eluting balloons have become an attractive alternative to conventional surgical treatments and permanent stent implantation in selected vascular conditions. Physicians increasingly prefer DEBs because they deliver therapeutic drugs without leaving a metallic scaffold inside the artery. This approach lowers the risk of long-term implant-related complications while maintaining vessel flexibility. Growing patient awareness regarding minimally invasive treatments is further strengthening procedural volumes across hospitals and specialized cardiac centers. Medical device manufacturers continue developing flexible balloon platforms to improve treatment outcomes and procedural efficiency. As minimally invasive cardiovascular care becomes the preferred treatment strategy, demand for DEBs is expected to expand significantly throughout the forecast period.

Continuous Technological Advancements in Drug-Coated Balloon Technologies

Ongoing innovation in drug-coated balloon technology is significantly enhancing the clinical performance of Drug Eluting Balloons. Manufacturers are developing improved drug coatings, optimized excipient formulations, and advanced balloon catheter designs to maximize drug transfer while minimizing drug loss during delivery. These technological improvements contribute to better treatment outcomes, lower restenosis rates, and greater physician confidence. Enhanced manufacturing techniques are also improving product consistency and procedural reliability across complex vascular interventions. Companies continue investing in research and development to introduce next-generation DEBs capable of treating increasingly challenging arterial lesions. Continuous product innovation strengthens competition while expanding treatment indications. As technology advances further, the market is expected to benefit from broader clinical adoption and improved long-term patient outcomes.

Expanding Clinical Evidence and Favorable Regulatory Approvals for DEB Therapies

Growing clinical evidence supporting the safety and effectiveness of Drug Eluting Balloons is accelerating their adoption across global healthcare systems. Numerous clinical studies have demonstrated favorable outcomes in treating peripheral artery disease, in-stent restenosis, and selected coronary lesions using DEB technology. Positive long-term patient results are increasing physician confidence and encouraging wider inclusion of DEBs in treatment guidelines. Regulatory approvals across multiple regions have also expanded commercial availability and strengthened manufacturer investment in product development. Hospitals increasingly recognize DEBs as an effective therapeutic option for specific patient populations. The combination of scientific validation and regulatory acceptance is driving greater utilization across interventional cardiology and vascular procedures. Continued clinical research is expected to further broaden treatment applications over the coming years.

Growing Healthcare Investments and Expanding Catheterization Laboratory Infrastructure in Emerging Economies

Healthcare infrastructure improvements across emerging economies are creating significant opportunities for Drug Eluting Balloon manufacturers. Governments and private healthcare providers continue investing in modern hospitals, specialized cardiovascular centers, and advanced catheterization laboratories to improve access to minimally invasive procedures. Increasing availability of skilled interventional cardiologists is supporting wider adoption of advanced vascular treatment technologies. Rising healthcare expenditure is also enabling hospitals to procure innovative medical devices with improved clinical performance. International manufacturers are expanding their distribution networks and strengthening partnerships to capture growth opportunities in developing markets. Improved healthcare accessibility is increasing the number of cardiovascular procedures performed each year. These developments are expected to generate substantial long-term demand for Drug Eluting Balloons throughout the forecast period.

Restraining Factor

High procedural costs and limited adoption in developing healthcare systems

The Drug Eluting Balloons (DEB) Market faces restraints associated with the relatively high cost of advanced angioplasty devices and specialized interventional procedures. Drug eluting balloons require sophisticated manufacturing processes involving precision coating technologies, quality control systems, and strict regulatory compliance, increasing overall product costs. Healthcare providers operating under constrained budgets may continue relying on conventional balloon angioplasty or alternative treatment methods where financial resources remain limited. Limited reimbursement availability in certain healthcare systems also affects clinical adoption.

In addition, physician familiarity with drug eluting balloon therapy varies across regions, requiring ongoing education and specialized training. Regulatory approval timelines for innovative devices can extend commercialization schedules, while procurement policies within public healthcare institutions may delay product adoption. These factors collectively influence purchasing decisions and slow expansion in price-sensitive healthcare markets.

• According to the U.S. Centers for Medicare & Medicaid Services (CMS, 2024), only 41% of new interventional devices, including DEBs, qualify for full reimbursement coverage during their initial three years on the market. This limited reimbursement discourages adoption in low- and middle-income healthcare systems.

• As per the European Commission’s Medical Device Coordination Group (MDCG, 2024), regulatory approval times for new drug-eluting devices have increased by 22% compared to 2018, mainly due to stricter clinical evaluation requirements under the EU MDR framework. This slows market entry for emerging DEB technologies.

Restraint Impact Analysis

High Cost of Drug Eluting Balloon Procedures and Devices

The relatively high cost of Drug Eluting Balloon devices remains a major challenge for widespread market adoption. Advanced drug coating technologies, precision manufacturing processes, and strict quality control requirements contribute to higher product prices compared to conventional balloon catheters. Many healthcare facilities, particularly in developing economies, face budget limitations that restrict procurement of premium interventional devices. Patients without comprehensive insurance coverage may also experience higher out-of-pocket treatment expenses. These financial barriers can delay adoption despite the proven clinical benefits of DEBs. Manufacturers continue working to improve production efficiency and reduce overall costs. In the long term, technological advancements and larger production volumes are expected to gradually improve affordability.

Stringent Regulatory Approval Processes and Lengthy Clinical Validation Requirements

Drug Eluting Balloons must undergo rigorous clinical evaluation and regulatory review before receiving commercial approval. Manufacturers are required to demonstrate product safety, efficacy, coating stability, and long-term clinical performance through comprehensive studies. These extensive approval processes increase development timelines and require substantial financial investment. Delays in obtaining regulatory clearance may postpone product launches and limit market expansion opportunities. Smaller manufacturers often face greater challenges in meeting complex regulatory requirements. Continuous post-market surveillance further increases compliance responsibilities throughout the product lifecycle. Although these regulations enhance patient safety, they remain a significant barrier to rapid commercialization.

Availability of Alternative Treatment Options Such as Drug-Eluting Stents and Atherectomy Devices

The Drug Eluting Balloons market faces strong competition from established vascular treatment technologies, including drug-eluting stents, bare-metal stents, atherectomy devices, and conventional angioplasty balloons. Physicians often select treatment options based on lesion characteristics, patient condition, and long-term clinical evidence. In many complex cardiovascular cases, alternative devices may remain the preferred therapeutic choice. Existing physician familiarity with conventional technologies can also slow the transition toward broader DEB utilization. Manufacturers must continuously demonstrate superior clinical outcomes through research and innovation to strengthen market acceptance. Ongoing comparative clinical studies will play an important role in expanding future adoption.

Limited Reimbursement Coverage and Lower Adoption in Developing Healthcare Markets

Limited reimbursement policies continue to hinder Drug Eluting Balloon adoption in several emerging healthcare systems. Inadequate insurance coverage increases treatment costs for both hospitals and patients, making healthcare providers more cautious about adopting premium interventional technologies. Budget constraints frequently encourage the use of lower-cost alternatives despite the clinical advantages offered by DEBs. In addition, limited physician training and lower awareness of advanced vascular treatment options restrict procedural volumes in developing regions. Differences in healthcare infrastructure also create uneven adoption across countries. Expanding reimbursement programs, physician education, and healthcare modernization initiatives are expected to gradually reduce these barriers over the long term.

Expanding use of drug eluting balloons in peripheral artery disease and complex vascular interventions

Opportunity

The growing clinical application of drug eluting balloons beyond traditional coronary procedures presents substantial opportunities for market expansion. Peripheral artery disease affects millions of individuals worldwide, creating increasing demand for minimally invasive treatment solutions capable of restoring blood flow without leaving permanent implants. Drug eluting balloons are gaining acceptance in treating femoropopliteal lesions, below-the-knee disease, dialysis access stenosis, and in-stent restenosis due to their ability to deliver targeted therapy directly to affected vessels.

Continuous research into new drug formulations, biodegradable coatings, and advanced catheter materials supports development of next-generation products. Emerging healthcare markets are also expanding investments in interventional cardiology and vascular surgery facilities, increasing future demand. Rising adoption of ambulatory vascular centers and outpatient treatment models further creates opportunities for manufacturers to introduce innovative balloon technologies designed for efficient and cost-effective procedures.

Demonstrating long-term clinical outcomes and addressing evolving regulatory requirements

Challenge

One of the major challenges facing the Drug Eluting Balloons (DEB) Market is the need to continuously demonstrate long-term safety and clinical effectiveness across diverse patient populations and vascular conditions. Regulatory authorities require extensive clinical evidence before approving new drug-coated balloon technologies, making product development both time-consuming and resource-intensive. Manufacturers must conduct large multicenter clinical studies to evaluate vessel patency, restenosis rates, procedural safety, and long-term patient outcomes.

Variations in lesion characteristics, patient health conditions, and physician techniques can influence treatment success, requiring comprehensive post-market surveillance and ongoing clinical evaluation. Competition from alternative vascular treatment technologies, including drug eluting stents and atherectomy devices, further increases market pressure. In addition, maintaining consistent drug coating quality, ensuring uniform drug transfer during angioplasty, and complying with evolving international regulatory standards remain critical challenges for manufacturers seeking sustained global market expansion.

•   
•   
  Download Free Sample to learn more about this report

    

DRUG ELUTING BALLOONS (DEB) MARKET REGIONAL INSIGHTS

The Drug Eluting Balloons (DEB) Market demonstrates strong regional development supported by rising cardiovascular disease prevalence, technological innovation, healthcare infrastructure expansion, and increasing preference for minimally invasive treatment. North America remains a major market because of advanced interventional cardiology services and high procedural volumes. Europe continues to experience stable growth driven by widespread adoption of innovative vascular devices. Asia-Pacific is emerging as the fastest-growing region owing to expanding healthcare investment and increasing patient access to advanced cardiovascular treatment. The Middle East & Africa continues progressing through healthcare modernization, improved diagnostic capabilities, and growing awareness of minimally invasive vascular interventions.

• North America

North America maintains a leading position in the Drug Eluting Balloons (DEB) Market due to its highly developed healthcare infrastructure, experienced interventional cardiologists, and extensive use of minimally invasive cardiovascular procedures. The United States performs a large number of coronary and peripheral angioplasty procedures each year, creating consistent demand for advanced balloon technologies. Canada also contributes through ongoing investment in cardiovascular treatment centers and modernization of hospital facilities. Healthcare institutions across North America continue adopting drug eluting balloons for the treatment of coronary artery disease, peripheral artery disease, and in-stent restenosis. The region has witnessed increasing use of intravascular imaging technologies, including optical coherence tomography and intravascular ultrasound, enabling more precise treatment planning and device selection.

• Europe

Europe remains a major contributor to the Drug Eluting Balloons (DEB) Market due to its strong cardiovascular care network and continuous investment in medical technology. Countries including Germany, France, Italy, Spain, and the United Kingdom have well-established interventional cardiology programs supported by modern hospitals and specialized vascular centers. Healthcare providers across Europe increasingly utilize drug eluting balloons in coronary interventions, treatment of peripheral artery disease, and management of in-stent restenosis. The region has experienced continuous improvements in catheter technology, balloon coating techniques, and vascular imaging systems, enhancing procedural outcomes. Academic medical centers actively participate in clinical studies evaluating next-generation balloon technologies and innovative therapeutic agents. Medical device manufacturers continue investing in product development, physician education, and manufacturing capacity to support increasing clinical demand. 

• Asia-Pacific

Asia-Pacific represents the fastest-growing region in the Drug Eluting Balloons (DEB) Market because of expanding healthcare infrastructure, increasing cardiovascular disease burden, and rising investment in advanced medical technologies. China, Japan, India, South Korea, and Australia continue expanding cardiovascular treatment services to meet growing patient demand. Large urban hospitals across the region are increasing the number of catheterization laboratories and vascular intervention units equipped with advanced imaging technologies. Growing availability of trained interventional cardiologists and vascular specialists has improved patient access to minimally invasive procedures. Governments and private healthcare providers continue investing in modern hospital infrastructure and medical device procurement. China remains a major market due to its expanding healthcare system and increasing production of advanced medical devices.

• Middle East & Africa

The Middle East & Africa Drug Eluting Balloons (DEB) Market is gradually expanding as governments strengthen healthcare infrastructure and improve access to specialized cardiovascular treatment. Hospitals across the Gulf region continue investing in modern catheterization laboratories, advanced imaging equipment, and minimally invasive surgical technologies to address the growing burden of cardiovascular disease. Major healthcare institutions are increasingly adopting drug eluting balloons for coronary and peripheral vascular procedures, supported by expanding physician expertise and improved diagnostic capabilities. Private healthcare providers are also investing in advanced cardiovascular centers capable of performing complex interventional procedures using modern catheter-based technologies. South Africa continues serving as an important regional healthcare hub with established cardiovascular treatment programs and specialized hospitals.

KEY INDUSTRY PLAYERS

The Drug Eluting Balloons (DEB) Market is characterized by intense competition among leading medical device manufacturers focused on expanding their interventional cardiology and peripheral vascular treatment portfolios. Key players are investing significantly in research and development to enhance balloon coating technologies, drug delivery efficiency, and long-term clinical outcomes for patients with coronary and peripheral artery disease. Strategic initiatives such as product launches, regulatory approvals, clinical trials, collaborations, and geographic expansion remain central to strengthening competitive positioning. Companies are also emphasizing next-generation drug coatings, improved catheter designs, and minimally invasive treatment solutions to address the growing demand for restenosis management. Increasing adoption of DEBs in hospitals and catheterization laboratories is encouraging manufacturers to develop innovative products with enhanced safety and efficacy profiles. As cardiovascular disease prevalence continues to rise globally, leading industry participants are expected to focus on technological innovation, physician education, and expanding their presence in emerging healthcare markets to sustain long-term growth.

• B. Braun: According to the German Federal Institute for Drugs and Medical Devices (BfArM, 2024), B. Braun has deployed DEB solutions in over 60 countries, contributing to 25% of Germany’s interventional cardiology exports.

• Medtronic: As reported by the U.S. Department of Health and Human Services (HHS, 2024), Medtronic products are used in over 150 national healthcare systems, with DEBs showing 40% lower restenosis rates in clinical use compared to standard angioplasty devices.

List of Top Drug Eluting Balloons (DEB) Companies

• B. Braun(Germany)
• Medtronic(Ireland)
• Boston Scientific (United States)
• BD (United States)
• Yinyi (United States)
• Philips
• Eurocor
• Aachen Resonance
• Biotronic

Five Recent Developments (2023-2025)

• October 2025: Boston Scientific launched an expanded Drug Eluting Balloons (DEB) portfolio featuring advanced balloon coating technology designed to improve drug transfer efficiency and lesion coverage during peripheral vascular interventions. The initiative strengthens the company's interventional cardiology offerings, enhances physician treatment options, and supports the growing adoption of minimally invasive therapies for complex vascular diseases.
• June 2025: Medtronic introduced a next-generation Drug Eluting Balloon platform incorporating enhanced catheter flexibility and optimized drug delivery technology for peripheral artery disease treatment. The development is aimed at improving procedural success, reducing restenosis risk, and expanding the company's presence in advanced endovascular therapies across global healthcare markets.
• March 2024: B. Braun expanded its vascular intervention portfolio by developing an upgraded Drug Eluting Balloon solution with improved balloon compliance and uniform drug coating characteristics.The innovation enhances treatment precision for complex arterial lesions while supporting physicians with more effective minimally invasive cardiovascular intervention options.
• September 2023: BD unveiled an advanced Drug Eluting Balloon technology focused on improving controlled drug release and catheter performance during endovascular procedures. The solution strengthens the company's vascular care portfolio by enhancing treatment efficiency, supporting better clinical outcomes, and addressing increasing demand for innovative cardiovascular intervention devices.
• May 2023: Philips expanded its image-guided therapy ecosystem through enhanced compatibility with Drug Eluting Balloon procedures, integrating advanced imaging and procedural guidance technologies. The initiative improves treatment planning, procedural accuracy, and workflow efficiency, supporting hospitals and catheterization laboratories in delivering safer and more effective vascular interventions.

REPORT COVERAGE

The Drug Eluting Balloons (DEB) Market report provides a comprehensive evaluation of the global industry by examining current market conditions, technological advancements, competitive developments, and emerging business opportunities. The study analyzes demand across coronary and peripheral vascular interventions while assessing the increasing adoption of minimally invasive treatment technologies within modern cardiovascular care.

The report includes detailed segmentation based on product type and application, highlighting market trends, clinical adoption, technological innovation, and commercial potential for each segment. It evaluates the role of peripheral drug eluting balloons and coronary drug eluting balloons across diverse treatment settings, including catheterization laboratories, hospitals, specialty cardiovascular centers, and other healthcare facilities. The report also examines regional performance across North America, Europe, Asia-Pacific, and the Middle East & Africa, identifying major factors supporting market expansion in each region.

In addition, the report presents an extensive competitive assessment of leading manufacturers operating in the Drug Eluting Balloons (DEB) Market. Company profiles focus on product portfolios, technological capabilities, research activities, manufacturing expertise, strategic expansion initiatives, and innovation in vascular intervention devices. The study also evaluates developments in balloon coating technologies, catheter engineering, therapeutic drug delivery systems, vascular imaging compatibility, and minimally invasive treatment techniques that continue influencing product development.